.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Home and remote blood-pressure monitoring can make hypertension management more responsive by increasing the frequency and reliability of measurements available to clinicians. Randomized studies of telemonitoring combined with pharmacist or clinician management have shown that patients can achieve better blood-pressure control than with usual care. The practical value lies in creating a feedback loop: readings are transmitted, reviewed, medication is adjusted and the patient receives reinforcement without waiting for the next clinic visit. For internal medicine, this model is particularly attractive for patients with high cardiovascular risk, variable office readings or difficulty attending frequent appointments. Technology alone, however, is not the intervention. Accurate cuff selection, validated devices, patient training and a defined clinician-response pathway are necessary. Digital exclusion and connectivity also need to be considered, especially in older or resource-constrained populations. The evidence supports remote monitoring as a complement to—not a replacement for—clinical assessment. Its greatest potential may be in shortening the time between recognizing uncontrolled blood pressure and intensifying treatment, converting hypertension care from periodic measurement into a continuous management process.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Home and remote blood-pressure monitoring can make hypertension management more responsive by increasing the frequency and reliability of measurements available to clinicians. Randomized studies of telemonitoring combined with pharmacist or clinician management have shown that patients can achieve better blood-pressure control than with usual care. The practical value lies in creating a feedback loop: readings are transmitted, reviewed, medication is adjusted and the patient receives reinforcement without waiting for the next clinic visit. For internal medicine, this model is particularly attractive for patients with high cardiovascular risk, variable office readings or difficulty attending frequent appointments. Technology alone, however, is not the intervention. Accurate cuff selection, validated devices, patient training and a defined clinician-response pathway are necessary. Digital exclusion and connectivity also need to be considered, especially in older or resource-constrained populations. The evidence supports remote monitoring as a complement to—not a replacement for—clinical assessment. Its greatest potential may be in shortening the time between recognizing uncontrolled blood pressure and intensifying treatment, converting hypertension care from periodic measurement into a continuous management process.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
